Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Quiz|Articles|March 18, 2024
Measles and the Collective American Memory: 3 Questions
Author(s)Terry Brenneman, MD
Measles cases are edging up in the US again as MMR vaccination rates continue to decline. Have parents forgotten the Ohio outbreak of 2022? Have you? Find out, here.
Advertisement
As of early March 2024, 41 documented cases of measles have been reported in 15 states, a sobering reminder of the decline in US MMR immunization rates. Is is possible the collective memory of US parents is just too short for the 2022 measles outbreak in Ohio? For clinicians at work in primary care, it's worth a look back at the outbreak and its consequences. The ages of the infected ranged from 6 months to 15 years. The index cases were some unvaccinated persons returned from east Africa.
Test your memory with 3 questions that include a hypothetical clinic scenario.
Question 1. Of the 85 reported cases in this central Ohio outbreak, what percentage had received at least one MMR vaccine?
Advertisement
Related to this article
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
An EHR-integrated tool matched manual CKD and cardiovascular risk assessments in 60 patients and showed promise for improving risk-based kidney care in primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
Advertisement
Advertisement
Trending on Patient Care Online
1
New Schizophrenia Treatment Addresses Long-Standing LAI Barriers
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
New Study Finds Low Initiation, Persistence With Menopause Hormone Therapy
4
Menopause Hormone Therapy Gaps Raise Questions for Primary Care
5